Citius Oncology Files 8-K Report
Ticker: CTOR · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1851484
Sentiment: neutral
Topics: 8-k, disclosure, corporate-event
TL;DR
CITIUS filed an 8-K today, check for "Other Events" updates.
AI Summary
On August 18, 2025, Citius Oncology, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company is incorporated in Delaware and its principal executive offices are located at 11 Commerce Drive, Cranford, NJ.
Why It Matters
This 8-K filing signals a material event or change for Citius Oncology, Inc., requiring immediate disclosure to investors.
Risk Assessment
Risk Level: medium — An 8-K filing indicates a significant event, but the specific nature of the 'Other Events' requires further investigation to assess the precise risk.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- August 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
- TenX Keane Acquisition (company) — Former company name
- 20210315 (date) — Date of former company name change
FAQ
What specific 'Other Events' are disclosed in this 8-K filing by Citius Oncology, Inc.?
The provided text of the 8-K filing does not detail the specific 'Other Events'; it only indicates that this is the item being reported.
When was this 8-K filing submitted?
The filing was made on August 18, 2025.
What is Citius Oncology, Inc.'s principal executive office address?
The principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
What was Citius Oncology, Inc. formerly known as?
The company was formerly known as TenX Keane Acquisition.
What is the SIC code for Citius Oncology, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 13.2 · Accepted 2025-08-18 17:26:25
Filing Documents
- ea0253763-8k_citius.htm (8-K) — 23KB
- 0001213900-25-078018.txt ( ) — 185KB
- ctor-20250818.xsd (EX-101.SCH) — 3KB
- ctor-20250818_lab.xml (EX-101.LAB) — 33KB
- ctor-20250818_pre.xml (EX-101.PRE) — 22KB
- ea0253763-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. Citius Oncology, Inc. today filed a prospectus supplement to its registration statement on Form S-1 that was declared effective on July 15, 2025, pursuant to which it sold common stock and warrants in a public offering on July 17, 2025. The prospectus supplement is necessary to keep the registration to incorporate by reference into the Form S-1 registration statement. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: August 18, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2